MANE vs MAZE
MANE: VeraDermics is a clinical-stage biotech developing an oral, extended-release minoxidil formulation (VDPHL01) to address the 80 million Americans with pattern hair loss who lack effective, convenient, non-hormonal treatment options. MAZE: Maze Therapeutics leverages human genetics data and its Compass platform to discover and develop novel therapeutic candidates across multiple disease indications.
Side-by-side fundamentals
| Metric | MANE | MAZE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $109.85 | $28.49 | |
| Market cap as of 2026-07-23 | $4.5B | $1.6B | |
| Net margin as of 2026-07-23 | n/a | +11.0% | |
| Operating margin as of 2026-07-23 | n/a | +34.4% | |
| ROE as of 2026-07-23 | -48.8% | -36.6% | MAZE higher |
| ROA as of 2026-07-23 | -45.9% | -31.8% | MAZE higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.11 | MANE lower |
| Beta as of 2026-07-23 | -0.59 | 1.10 | |
| 1-year return as of 2026-07-22 close | +190.0% | +75.9% | MANE higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.